(fifthQuint)Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No.

 5).

 Subjects with atopic dermatitis (AD) will be treated with either tralokinumab or dummy treatment (placebo) for 16 weeks.

 All subjects will receive 2 vaccines at Week 12.

 The vaccines are: 1.

 Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine.

 This combination vaccine is also known as the Tdap vaccine and is used to prevent these 3 diseases.

 2.

 Meningococcal vaccine.

 This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning.

 The primary objective of the trial is to demonstrate non-inferiority of tralokinumab versus placebo with respect to immune responses to concomitantly administered vaccines.

 The secondary objective is to evaluate efficacy of tralokinumab concomitantly administered with vaccines.

.

 Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No.

 5)@highlight

The purpose of this trial is to test if treatment with the trial drug, tralokinumab, can affect the body's immune response to vaccines.

 The trial will also evaluate the efficacy of tralokinumab when it is given concomitantly with vaccines.

 The trial includes a screening period of 2 to 6 weeks, a treatment period of 16 weeks (Weeks 0 to 16), and a 14-week off-treatment follow-up period for the assessment of safety (Weeks 16 to 30).

 Eligible subjects may transfer to an open-label, long-term trial at Week 16 or later.

